Introduction
============

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that usually leads to death within 1-5 years period of diagnosis [@B1] ALS is a neuromuscular disease in which motor neurons located in the brain or spinal cord degenerate, giving rise to muscular weakness and atrophy. This loss of motor neurons leads to fatal paralysis and death and is the most frequent disease of motor neurons [@B1]. The vast majority of ALS cases are sporadic (about 95%), whereas only a few are familial. In familial ALS, a number of mutations in several genes have been described, including Cu/Zn-superoxide dismutase (SOD1) [@B2], [@B3]. Relationships between ALS and other neurodegenerative diseases have been noted, particularly with frontotemporal dementia (FTD) [@B4]. As occurs with most neurodegenerative diseases, the etiology of ALS remains unknown despite intensive research. The existence of aberrant protein aggregates inside neurons and glial cells constitutes an important hallmark for the classification of neurodegenerative diseases. In ALS, several proteins have been identified forming aggregates inside the cells in most patients. This is exemplified by ubiquitinated inclusions, as well as detection of transactive response (TAR)-DNA binding protein 43 (TDP-43) and the fused in sarcoma protein (FUS) in cytoplasmic granules [@B5]-[@B7]. TDP-43 exhibits a predominant nuclear localization, shuttling between the nucleus and cytoplasm, and is widely expressed in most cell types [@B8]. TDP-43 can interact with both DNA and RNA, and also with some members of the heterogeneous nuclear ribonucleoprotein family, participating in the process of transcription and splicing [@B9], [@B10]. In this way, TDP-43 modulates a number of cellular functions including apoptosis [@B11]. FUS protein is also expressed in a wide array of cells, and shuttles between nucleus and cytoplasm with the capacity to interact with nucleic acids. FUS is involved in a number of cellular processes, including transcription and RNA processing, cell proliferation and DNA repair [@B12]. Together with TDP-43 and FUS, a number of related proteins are under investigation as potential participants in ALS pathogenesis, including hnRNPA1, TAF15 and EWSR1 [@B6], [@B13]-[@B15].

The presence of cytoplasmic aggregates constitutes the basis for classification of different subtypes of both ALS and FTD, and it has been suggested that different protein aggregates may govern pathological mechanisms [@B4]. However, it is still unclear what practical value this classification provides for diagnosis and for future potential therapies. The central concept of ALS research is that mutations in some genes may lead to the synthesis of aberrant proteins that are misfolded, giving rise to cytoplasmic aggregates that are pathological for the correct functioning of motor neurons [@B16]. Accordingly, a number of mutations have been identified in TARDBP, the gene encoding TDP-43, and in the FUS gene [@B16]. These mutations only account for a small percentage of ALS cases; consequently, the number of candidate ALS genes is steadily increasing [@B16]. An intriguing question in the field is why mutations in different genes manifest after many years in the patient´s lifetime and also why these protein inclusions are specifically pathological for motor neurons and are not present in other cell types.

Similarities exist between ALS and Alzheimer\'s disease (AD), with regards to the presence of hyperphosphorylated tau protein in some neural cells and the formation of amyloid peptide [@B17], [@B18]. Recently, we have reported that fungal infection may play a part in the development of AD [@B19]-[@B21]. Fungal proteins and polysaccharides are present in the blood of AD patients and, more significantly, fungal proteins and DNA can be detected in brain samples from AD patients. Further, direct visualization of intracellular fungal infection in neurons from the frontal cortex of AD patients could be demonstrated with fungal-specific antibodies. Interestingly, chitin-like polysaccharides have been detected in AD brains and chitinase is elevated in cerebrospinal fluid (CSF) from AD patients [@B22]-[@B24]. To our knowledge, the possibility that a microbial infection could be the cause of ALS has thus far not been considered, although some correlations has been found between sporadic ALS and enterovirus infections [@B25]. More recently, elevated chitinase levels have been detected in CSF from ALS patients [@B26], [@B27]. In the present work, we have evaluated the existence of fungal proteins and DNA in CSF and brain samples from ALS patients. Our findings provide evidence for disseminated fungal infection in the central nervous system (CNS) in ALS patients.

Materials and Methods
=====================

Description of patients
-----------------------

The samples analyzed in this study correspond to cerebrospinal fluid (CSF) and tissue sections obtained from brain donors diagnosed with ALS. Details about the age and gender of each patient are listed in [Supplementary Tables](#SM1){ref-type="supplementary-material"} SI and SII. All samples were supplied by Banco de Tejidos, Fundación CIEN (Centro de Investigación de Enfermedades Neurologicas). The Ethics Committee of Universidad Autónoma de Madrid approved the study. The transfer of samples was performed according to national regulations concerning research on human biological samples. For all cases, written informed consent is available. All ethico-legal documents of the brain bank, including written informed consent, have been approved by an ethics committee external to the bank. The data obtained in this study was analyzed by an observer blinded to the diagnosis.

Preparation of antifungal antibodies
------------------------------------

Rabbit antisera against *Candida famata*, *C. albicans*, *C. parapsilosis*, *C. glabrata*, and *Penicillium notatum* were obtained by inoculation of 1 or 2 mg of dried fungi (after autoclaving and lyophilization) in 0.5 ml PBS. Rabbit antiserum against peptide B tubulin-KLH (keyhole limpet hemocyanin) was purchased from PolyPeptide Group (Strasbourg, France). Each inoculum had been previously mixed with an equal volume of Freund\'s adjuvant. Rabbits were inoculated up to three times every three weeks and the antibody titer and specificity of the sera were tested by immunohistochemistry and immunoblotting. For antiserum against recombinant enolase of *C. famata*, pMAL-enolase was cloned using 5´Eno and 3´Eno primers (CGCCGCGGATCCATGGCCGTCACTAAGTTATT and CGCCGCGTCGACTTATAATTGAGAAGCAGCGT, respectively) and expressed in *E. coli* BL21 for purification *via* Ni-NTA Superflow (Promega) chromatography. Purified protein was then inoculated in rats, as described with rabbits.

Slot-blot assay of fungal proteins
----------------------------------

To estimate the presence of fungal protein antigens, CFS was diluted and filtered through nitrocellulose membranes. A 200 µl volume of different CFS dilutions (1:10) in TBS was added to each well. Samples were blotted onto a 0.45-microns nitrocellulose membrane (Bio-Rad) previously hydrated in TBS for 10 minutes, using the Bio-Dot SF apparatus (Bio-Rad). After blotting, the membrane was processed and developed as described [@B28], [@B29]. The primary antibodies, rabbit polyclonal antibodies raised against *C. famata*, *C. albicans*, *C. parapsilosis, C. glabrata, P. notatum*and peptide of beta tubulin KLH, were used at a 1:500 dilution. A donkey anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) was used at a 1:5000 dilution. Rat polyclonal antibody raised against *C. famata* enolase of was used at a 1:200 dilution. A rabbit anti-rat IgG horseradish peroxidase-conjugated secondary antibody (Sigma) was used at a 1:5000 dilution. Densitometric analysis of the film was carried out using a GS-800 Calibrated Densitometer (Bio-Rad). The median of three different experiments and the cut-off of these values are indicated in the Results section. In previous studies, we established that values below 10 in this assay should be considered negative, between 10 and 20 as uncertain, and values above 20 as positive. In the latter case, values between 20 and 50 are considered low, between 50 and 80 as moderate and above 80 as high.

DNA Extraction from CSF
-----------------------

To extract DNA from CSF samples we followed this procedure: 20 µl of proteinase K (\>600mAU/ml) was added to 150 µl of CSF and 200 µl buffer AL (QIAmp Kit, Qiagen) and mixed for 15 s. 200 µl ethanol was added to each sample after incubation at 56ºC for 10 min, followed by mixing by pulse-vortexing for 15 s. The mixture was then applied to the QIAamp Mini spin column and centrifuged at 8,000 rpm for 1 min. Afterwords, 500 µl buffer AW was added and samples were centrifuged at 8,000 rpm for 1 min. Next, 500 µl buffer AW2 was applied, followed by centrifugation at 14,000 rpm for 3 min. Finally, each sample was suspended in 40 µl distilled water. DNA from extracts was quantified with a NanoDrop® ND-1000 UV-Vis Spectrophotometer. As negative controls we employed three samples of tri-distilled filtered water.

DNA Extraction from tissue
--------------------------

Brain samples were used to extract DNA using the QIAmp (Qiagen) genomic DNA isolation kit as follows: 20 µl proteinase K (\>600mAU/ml) and 180 µl of buffer ATL were added to 25 mg of brain tissue, followed by pulse-vortexing for 15 s. Then, it was incubated at 56ºC for 1-3 h with agitation. A 200 µl volume of buffer AL was added to each sample followed by vortexing for 15 s and incubation at 70ºC for 10 min. 200 µl ethanol was added to each sample with vortexing for 15 s. The mixture was applied to the QIAamp Mini spin column and centrifuged at 8,000 rpm for 1 min. After, 500 µl buffer AW was applied to the column, which was centrifuged at 8,000 rpm for 1 min. 500 µl buffer AW2 was applied and the column was centrifuged at 14,000 rpm for 3 min. Finally, each sample was collected in 40 µl distilled water and quantification of DNA was carried out with a NanoDrop® ND-1000 UV-Vis Spectrophotometer and. negative controls three samples of tri-distilled filtered water were employed.

Design of oligonucleotides
--------------------------

ITS oligonucleotides. The gene sequences of 5.8S and 18S rRNA, as well as internal transcribed spacer 1 (ITS 1) region from several organisms (*C. albicans, C. famata*, *C. parapsilosis*, *C. glabrata*, *Rhodotorula mucilaginosa*, *Pichia guilliermondii*, *Cryptococcus neoformans* and *Homo sapiens*) were accessed *via* the GenBank database and were aligned using the Clustal W sequence analysis package. Multiple potential primer-binding sites for this panfungal primer pair were chosen by comparing regions of *Candida* homologous with regions of the fungal group within the fungal kingdom with the most divergent DNA sequences and regions of *Candida* incongruous with the human DNA sequence. The primer selection was optimized for melting temperature equivalence, lack of duplex, hairpin, or primer-dimer formation, and internal stability by using OLIGO software (Amplify).

Nested PCR
----------

A number of measures were used to avoid PCR assay contamination. Thus, we used separate rooms and glassware supplies for PCR set-up and products, aliquoted reagents, positive-displacement pipettes, aerosol-resistant tips, and multiple negative controls. DNA samples obtained from CSF or brain tissue were analyzed by nested PCR using the ITS-1 primers. The first PCR was carried out with 4 μl of DNA incubated at 95°C for 10 min and amplified with 30 cycles of 45 s at 94°C, 1 min at 57.3°C, and 45 s at 72°C. The oligonucleotides used were forward ^1448^5´ GTTCTGGGCCGCACGGG 3′^1465^ and reverse ^106R^5′ GGCAAAGATTCGATGATT 3´^88R^ The second PCR was carried out using one of two primer sets; in one instance, 2A ITS-1 primers were employed, whereas in the second instance 2B ITS-1 primers ( ITS1-ITS2, panfungal primers) were used. The second PCR was carried out with 0.5 μl of the product obtained in the first PCR, and was amplified with 2A ITS-1 primers with 30 cycles of 45 s at 94°C, 1 min at 52°C, and 45 s at 72°C. The oligonucleotides used were forward ^1781^5′ GCGTCTA GACCTGCGGAAGGATCA 3´^1798^and reverse ^20R^5′ GCGAAGCTT GATCCGTTGTTGAAA 3´^5R^. These primers contained extra nucleotides to provide a cloning site for the amplified PCR product. As an alternative second PCR, 2B ITS1-ITS2 primers were used. The second PCR was carried out with 0.5 μl of the product obtained in the first PCR and was amplified with 35 cycles of 45 s at 94°C, 1 min at 55°C, and 45 s at 72°C. The oligonucleotides used were forward ^1771^5´ TCCGTAGGTGAACCTGCGG 3´^1790^ and reverse ^50R^5´ GCTGCGTTCTTCATCGATGC 3´^30R^ which are the commonly used ITS1 and ITS2 primers developed by [@B30]. Amplified products were analyzed by agarose gel electrophoresis and stained with ethidium bromide. We wish to indicate that these PCR assays can amplify the vast majority of fungal DNA, however some fungal species may not be detected because of the primers or the conditions employed. Moreover, different combinations of these primers may provide a better coverage of other species.

Mass Spectrometry Analysis
--------------------------

Initially, proteins from brain samples were separated by polyacrylamide gel electrophoresis (PAGE) under reducing conditions according to Laemmli, with a 12.5% separating gel and a 5% stacking gel. Protein staining was carried out with GelCode Blue Stain Reagent (Thermo Scientific). Separation of proteins and gel excision were carried out essentially as previously described [@B19]. Twelve stained sections (about 0.5-0.8 cm) were excised from the gel, and proteins were in-gel digested with trypsin, after reduction and alkylation. This procedure was performed after drying, gel bands were destained in acetonitrile:water (ACN:H~2~O, 1:1) and were reduced and alkylated. Thus, disulfide bonds from cysteinyl residues were reduced with 10 mM DTT for 1 h at 60ºC, and then thiol groups were alkylated with 55 mM iodoacetamide for 1 h at room temperature in the dark. The proteins were then digested *in situ* with sequencing grade trypsin (Promega, Madison, WI). The gel pieces were shrunk by dehydration in acetonitrile, which was then removed. The gel pieces were then dried in a vacuum centrifuge. Afterwards, the dried gel pieces were re-swollen in 50 mM ammonium bicarbonate pH 8.8 with 12.5 ng/μl trypsin for 1 h in an ice-bath. The digestion buffer was removed and gels were covered again with 50 mM NH~4~HCO~3~ and incubated at 37°C for 12 h. Digestion was stopped by the addition of 1% TFA. Whole supernatants were dried down and then desalted on OMIX C18 Pipette tips (Agilent) for the mass spectrometry analysis. The peptide extracts were combined into 3 pools of discontinuous bands, to reduce the analysis by LC-MS to 4 runs per sample. The desalted protein digest was dried, resuspended in 10 μl of 0.1% formic acid and analyzed by RP-LC-MS/MS in an Easy-nLC II system coupled to a LTQ-Orbitrap-Velos-Pro hybrid mass spectrometer (Thermo Scientific). Concentration of peptides (on-line) was carried out by reverse phase chromatography using a 0.1 mm × 20 mm C18 RP precolumn (Thermo Scientific), and then separated using a 0.075mm x 150 mm C18 RP column (Thermo Scientific) operating at 0.3 μl/min. Elution of peptides was performed using two different gradients: a 120 or 180-min gradient from 5 to 40% solvent B (Solvent A: 0.1% formic acid in water, solvent B: 0.1% formic acid, 80% acetonitrile in water). ESI ionization was done using a Nano-bore emitter Stainless Steel ID 30 μm (Proxeon) interface. The Orbitrap resolution was set at 30,000. Peptides were detected in survey scans from 400 to 1600 amu (1 μscan), followed by twenty data dependent MS/MS scans (Top 20), using an isolation width of 2 u (in mass-to-charge ratio units), normalized collision energy of 35%, and dynamic exclusion applied during 30 second periods.

Mass spectrometry data processing
---------------------------------

Processing of the MS data was carried out as previously described [@B19]. Briefly, peptide identification from raw data was carried out using the SEQUEST algorithm (Proteome Discoverer 1.3, Thermo Scientific). Database searching was performed against uniprot-homo fasta and uniprot-fungi fasta.

Histological analysis
---------------------

Brain sections (5 μm) were fixed in 10% buffered formalin for 24 h and then embedded in paraffin following standard protocols. For immunohistochemical analysis, paraffin was removed and the tissues were rehydrated and boiled for 2 min in citrate buffer. After, samples were incubated 10 min with ammonium chloride. Subsequently, tissue sections were incubated 10 min with PBS/Triton X-100 0.1% and further incubated for 20 min with PBS/BSA 2%. Sections were then incubated overnight at 4^o^C with mouse monoclonal antibody raised against human α-tubulin at a 1:50 dilution, or rabbit polyclonal antibody raised against proteins obtained from *C. glabrata* at a 1:500 dilution. After this incubation, the sections were washed with PBS and incubated for 1 hour at 37ºC with donkey anti-mouse IgG secondary antibody conjugated to Alexa 555 (Invitrogen) for α-tubulin and donkey anti-rabbit IgG secondary antibody conjugated to Alexa 555 or Alexa 488 (Invitrogen) at a 1:500 dilution for anti-*C. glabrata*. Afterwards, tissue sections were stained with DAPI (Merck). Then, samples were treated with Autofluorescence Eliminator Reagent (Merck). Finally, sections were observed using a LSM710 confocal laser scanning microscope combined with the upright microscope stand AxioImager.M2 (Zeiss). The spectral system employed was Quasar + 2 PMTs. Zeiss ZEN 2010 Program.

Results
=======

Search of fungal infection in CSF from ALS patients. Presence of fungal antigens
--------------------------------------------------------------------------------

A highly sensitive slot-blot assay to analyze the presence of fungi in blood serum or CSF has been developed using specific antibodies against fungal antigens [@B20], [@B28], [@B31]. Samples are blotted onto a nitrocellulose membrane and then incubated with the corresponding primary antibody at the indicated dilution. Subsequently, the membrane is incubated with a peroxidase-conjugated secondary antibody and the film obtained is scanned. We have previously established the cut-off values to determine negative or positive results [@B31]. We first tested a number of antibodies raised against total fungal cells or purified enolase from *C. famata*, or a β-tubulin peptide specific for fungi. CSF samples from five ALS patients and from three controls (see [Supplementary Table](#SM1){ref-type="supplementary-material"} SI) were tested. Figure [1](#F1){ref-type="fig"} shows representative results obtained with anti-*C. albicans* and enolase antibodies. A positive control using yeast proteins and a negative control containing TBS were used. Certainly, CSF samples from ALS patients rendered a clear positive result. Densitometric quantification of this assay employed a panel of different antibodies is presented in Table [I](#TI){ref-type="table"} indicating the positive reactivity for fungal antigens in all five patients. As expected, values obtained in control CSF samples for a range of fungi were rather low. In contrast, slot-blot values from CSF of ALS patients were generally considerably higher. For example, CSF from patient 1 exhibited high values with several antibodies employed, including anti-*C. famata*, *C. albicans*, *C. glabrata*, enolase and β-tubulin. Further, high values were obtained in most cases with the anti-*C. albicans*, enolase and β-tubulin antibodies. Not all the antibodies exhibited a similar behavior, since in some instances the differences found with a given antibody were more pronounced between ALS and control CSFs. This may indicate that the fungal antigens present in ALS CSF immunoreact much better than other anti-fungal antibodies. For example, this is the case of values obtained with anti-*C. albicans* antibodies that rendered a median of 131.2 in ALS and 11.3 in controls, with a P=0.18 and the odds ratio of 8.0. Considering all the values of Table [I](#TI){ref-type="table"}, the results obtained are: P=0.01 and odds ratio=4.8. Overall, these results indicate that fungal antigens are present in CSF from ALS patients.

PCR assay of DNA isolated from CSF
----------------------------------

An additional sensitive method to assess fungal infection is PCR [@B32], [@B33]. This technique has the added advantage that, after amplification of variable internal transcribed spacer 1 (ITS1) present between the rRNA genes (see scheme Figure [2](#F2){ref-type="fig"}), followed by agarose electrophoresis, sequencing of the amplified products reveals the fungal species present. However, it must be considered that the bulk of the DNA obtained is from human origin and only a very small amount would be fungal. Due to the limited volume of CSF, DNA could not be obtained from one of the patient samples; nonetheless, DNA was obtained from four CSF samples and the ITS1 sequences were amplified by nested PCR. After the first PCR, the second amplification was carried out with two independent primer pairs, as detailed in materials and methods (see scheme, Figure [2](#F2){ref-type="fig"}). The first primer pair, 2A ITS1, has been previously employed successfully by us [@B19], [@B31]. The second primer pair, 2B ITS1, have been described as panfungal primers [@B34], although they do not completely hybridize with *Malassezia spp*. The use of different primers may serve to a better coverage of several fungal species. Moreover, future studies in this regard may benefit from the use of a wider range of primers to perform PCR studies. Notably, several products were amplified using 2A ITS1 primers in DNA extracted from CSF of ALS patients (Figure [2](#F2){ref-type="fig"}). In contrast, no products were obtained in control CSF samples or in controls for DNA extraction or PCR amplification without DNA, indicating that these amplified products were not due to contamination during DNA extraction or PCR amplification. DNA sequencing of the amplified products revealed the fungal species listed in Figure [2](#F2){ref-type="fig"}. Of interest, 2A ITS1 primers amplifed *Malassezia spp*. (Figure [2](#F2){ref-type="fig"}). More importantly, *C. albicans* was also detected in two patients (2 and 3). The use of the panfungal primers 2B ITS1 also revealed the presence of *C. albicans*DNA in these two patients. Additionally, *Rhodotorula mucilaginosa* was detected in patients 1 and 4 using the 2B ITS1 primer pair, but *Malassezia spp*. was not amplified. The possibility that DNA from other fungal species was present in lower amounts is not excluded by these results. Moreover, it is possible that fungal cells from some species, which are present in brain tissue, are not released to the CSF. Taken together, these results strongly suggest that DNA from several fungi is present in CSF from ALS patients.

Visualization of fungal infection in brain by immunohistochemistry
------------------------------------------------------------------

Given the above results in CSF, we next examined sections from the frontal cortex by immunohistochemistry using polyclonal rabbit antibodies raised against *C. glabrata*. Two individual fields are depicted for each sample (Figure [3](#F3){ref-type="fig"}). No immunofluorescence was found in the frontal cortex from three control individuals ([Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). In contrast, several neurons were immunopositive for *C. glabrata* and stained intracellular punctate bodies in the cytoplasm in ALS brain sections (Figure [3](#F3){ref-type="fig"}). These bodies resemble the intracellular morphology of other fungi, as reported previously [@B35], [@B36]. This fungal material was not observed in all neurons, because some of them were devoid of it. A wider film of one control and one ALS patient is shown in Figure [4](#F4){ref-type="fig"}. In this case, double immunofluorescence with anti-tubulin and anti-*C. glabrata* antibodies was carried out. The subcellular distribution of tubulin was similar to that reported for neurons in some neurodegenerative diseases [@B37], [@B38]. The control sample was devoid of fungal bodies whereas they were clearly observed in the ALS patient. Apart from the intracellular punctate fungal material some extracellular bodies were also apparent. The morphological appearance is similar to our recently described findings in neurons from patients diagnosed with AD and these fungal bodies were known as intramycosomes [@B21] or perhaps we can name them more adequately, endomycosomes. Both, ALS and AD share parallels, but it is possible that the fungal species that affect both types of patients are different, and the genetic background of these patients also differs. The most important conclusion from these results is that fungal bodies can be observed in neurons from brains of ALS patients. Obviously, these studies do not indicate the exact fungal species present in these samples.

Fungal DNA in brain samples
---------------------------

To analyze the potential fungal species present in brain samples from ALS patients, DNA was extracted from different CNS regions as indicated in Figure [5](#F5){ref-type="fig"}, and nested PCR was carried out as described using primers 1 in the first round and primers 2A in the second round. Interestingly, several DNA products were amplified in the three ALS patients analyzed, whereas no amplification was found in control sample (Figure [3](#F3){ref-type="fig"}). DNA sequencing of the isolated products resulted in the identification of the species, depicted in the bottom of Figure [5](#F5){ref-type="fig"}. Notably, several species could be identified from one patient and these species varied according to the CNS region analyzed. Further, different fungal species were detected in patients, although some were present in all three ALS patients. Accordingly, *Malassezia globosa* was present in most of the samples tested, whereas *Cryptococcus neoformans* was only detected in one sample. In our opinion, the most striking finding was that *C. albicans* appeared in all three patients. This yeast was also present in the CSF of several ALS patients (Figure [2](#F2){ref-type="fig"}) and it is acknowledged that *C. albicans* can be highly pathogenic; this also applies to the presence of *C. neoformans* in one patient. Possibly, the existence of different fungal species may account for the differences in the severity and evolution of disease observed between ALS patients. Results from the second PCR using panfungal primers (2B), revealed that, as before, different fungal species could be detected. *Trychoderma viridae* was evident in all samples, whereas *Cryptococcus magnus* appeared in the four samples of patient 6. Collectively, these findings show that fungal infection of the CNS in ALS patients can be detected by PCR analysis, and different fungal species can also be determined. However, we do not know if the species identified by PCR are exactly the ones observed by immunofluorescence.

Proteomic analyses of brain samples
-----------------------------------

Determination of the proteome of CSF or CNS from patients with neurodegenerative disease may serve to identify biomarkers for diagnosis, prognosis and evolution of each particular disease [@B39]-[@B42]. To our knowledge, no attempts have been made to identify fungal proteins in samples from ALS patients. Therefore, frontal cortex proteins from three ALS patients were initially separated by polyacrylamide gel electrophoresis and stained with Coomassie blue ([Supplementary Figure S2](#SM1){ref-type="supplementary-material"}). After gel staining, each lane was cut in 12 slices and digested with trypsin. Peptide extracts from three non-consecutive slices were pooled and analyzed by mass spectrometry. Consequently, four samples were analyzed by MS from each patient. Each sample was analyzed twice; the first analysis was carried out with a 120 min gradient and the second analysis with 180 min gradient, in order to obtain more peptides by increasing the gradient time. Each run was analyzed with the Proteome Discoverer (PD) 1.3 software, allowing the search for human and fungal proteins (Uniprot). In this manner, we could compare the peptides that are common to both human and fungi, to better discriminate which peptides were specific for fungi. Additionally, the peptides obtained from the 180 min gradient were analyzed with the Peaks 6 software, using the tool called PEAKS PTM which identifies post-translational modifications and variations due to potential mutations compiled in the Unimod library,as well as custom PTMs [@B43]. Each peptide identified as fungal by PD 1.3 was subjected to further scrutiny by: 1) confirmation of the identification quality by visual inspection of the spectra; 2) search of homology to homo sapiens peptides by BLAST (ExPASY BLAST) to assess the differences between the corresponding human and fungal peptides; 3) peaks 6 study of the sequences assigned for fungi and human.

The human proteins common to the three patients that were not present in a control recently published by our laboratory are listed in [Supplementary Table](#SM1){ref-type="supplementary-material"} SIII. These proteins can be grouped according to their cellular function (Figure [6](#F6){ref-type="fig"}). These proteins may constitute the basis for future ALS biomarkers.

Regarding the identification of fungal proteins, Table [II](#TII){ref-type="table"} summarizes the fungal peptides obtained in the four fractions A-D from the three ALS patients. Although many more peptides may be present, we only indicate in Table [II](#TII){ref-type="table"} the peptides that belong to fungi beyond any doubt. We are confident that the peptides corresponding to α- and β-tubulin are of fungal origin. The identification of tubulin by proteomic analyses is consistent with the fact that tubulin is an abundant cellular protein. Fungal peptides corresponding to actin have similarities to their human counterparts and could not therefore be unequivocally identified. Nevertheless, the important finding from proteomic analysis is that fungal tubulin is present in brain samples from ALS patients, further supporting the notion that fungal infection exists in the CNS of ALS patients.

Discussion
==========

The involvement of microbial infections in neurodegenerative diseases has been deliberated by several laboratories [@B44]-[@B47]. However, these studies have focused on viral or bacterial infections and less attention has been given to the possibility that fungal infections may be responsible for some of these diseases [@B48]. The notion that fungal infection may be involved in the etiology of multiple sclerosis (MS) and AD has been considered in several reports from our laboratory [@B19]-[@B21], [@B28], [@B31], [@B49]. This concept is consistent with a number of clinical symptoms and observations reported for these diseases. Similar to neurodegenerative disease, fungal infections are usually chronic and progressive if untreated. Neuroinflammation is also repeatedly observed in the majority of neurodegenerative diseases, including ALS, and the continuous presence of fungal pathogens in the CNS can provoke not only chronic inflammation, but also the sustained production of microbial products. Both inflammation and microbial products, or even intracellular fungal cells (endomycosomes), could lead to neuronal degeneration and death. Additionally, fungal infection could also account for the generation of granules of misfolded or aberrantly-processed proteins. Granular type may depend on a number of variables: 1) the subset of neural cells affected; 2) the individual fungal species infecting the CNS and the route of this infection; 3) the genetic background of the patient and, 4) the state of the immune system and the lifestyle of each individual. Differences in any of these parameters could give rise to different pathologies. Conversely, if some neurodegenerative diseases are caused by fungal infections, it is also logical that they will share several similarities [@B50]-[@B52]. Our previous reports have provided evidence for fungal infections in MS and AD patients. Strikingly, chitin-like polysaccharides have been found in brains from MS and AD patients [@B22], [@B23] and most probably as a consequence there are elevated levels of chitinase in AD CSF [@B24]. However, these researchers did not suggest the existence of fungal infection. The present work provides the first description of fungal proteins and DNA both in CSF and CNS from ALS patients. Furthermore, immunofluorescence analysis clearly demonstrated fungal infection within some neurons, whereas other neighboring cells were devoid of this material. These observations provide direct evidence for the concept that ALS patients suffer fungal infections in some neurons of the CNS and are in accord with proteomic and PCR results identifying several fungal species. The recent finding that CSF from ALS patients contains elevated levels of chitinase [@B26], [@B27] do also support the idea of fungal infection in these patients.

ALS is a heterogeneous disease in which the evolution and clinical symptoms vary widely between patients; consequently, the disease can progress rapidly in some patients, who die within one year from diagnosis, while other patients can survive several years after the onset of clinical symptoms. The presence of different fungal species in each patient may account for this behavior. A number of similarities have been observed between different neurodegenerative diseases, particularly between MS, AD and Parkinson\'s disease, as well as between ALS and FTD [@B4], [@B53]-[@B55]. Notably, some likenesses have also been reported between AD and ALS, including tangles of hyperphosphorylated tau in some neural cells from ALS patients with or without cognitive impairment, although in the latter there is a more widely distributed tau pathology [@B18], [@B56]. The existence of fungal infections both in AD and ALS patients also provides an explanation for the similarities reported between these diseases. It is well established that individual genetic background can determine the likelihood of fungal infections [@B57]-[@B59]. Also, the presence of particular mutations in different genes in ALS patients may dictate their predisposition for ALS. In familial ALS cases, the most represented gene mutations are in the SOD1 gene [@B3]. SOD, an antioxidant defense gene, is involved in the innate immune response to a number of pathogens including fungi [@B60], [@B61]. Therefore, it is perhaps not surprising that SOD1 mutations that may affect the immune response in ALS patients [@B62], [@B63] might confer a greater sensitivity to fungal infection.

An additional symptom shared by AD and ALS is the occurrence of neuroinflammation and infiltration of T-lymphocytes in some areas of the CNS or spinal cord [@B52], [@B64]-[@B68]. Also, modifications in the number of different subsets of circulating T-lymphocytes have been noted in both disorders [@B69]-[@B71], suggesting that there is a systemic alteration of the immune system in patients suffering from these diseases. Supporting the concept that neuroinflammation plays a part in ALS pathology, the number of regulatory T-lymphocytes correlates inversely with disease progression [@B72]. Neuroinflammation and T cell infiltration may be consistent with microbial infection [@B73]. In this regard, our present findings reveal fungal infection both in CSF and brain samples from patients with ALS. Strikingly, the immunofluorescence results are also consistent with the concept that some neural cells contain intracellular fungal material or endomycosomes. This low burden of infection, together with the fact that endomycosomes are very small (about 1 μm in diameter), provides an explanation for the hitherto elusive detection of this type of infection in ALS. If disseminated mycoses are responsible for ALS, this might explain why the disease appears suddenly in patients. Also, differences in the severity and evolution of clinical symptoms might be rationalized by the different fungal species, or even combinations of these species. Another possibility should be that immune tolerance to fungal infection is lost in these patients and inflammation provokes injury and clinical symptoms [@B74]. Our present observations not only open a new field for the investigation of ALS, but if they are correct, ALS patients would immediately benefit from antifungal therapies. In this sense, clinical trials should definitively clarify the potential participation of fungal infection in the pathology of ALS.
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![**Analysis of *C. albicans* and enolase antigens in CSF by slot-blot.** 20 μl CSF samples were diluted with 180 μl TBS and were blotted onto a nitrocellulose membrane, which was incubated with the rabbit antiserum against *C. albicans* or enolase or recombinant MBP-enolase (primary antibody) as indicated and afterwards incubated with a rabbit anti rat IgG (secondary antibody). Positive control: control + 200 ng yeast protein or purified MBP-enolase. Negative control: control - corresponds to TBS alone.](ijbsv11p0546g001){#F1}

![**PCR analysis of DNA obtained from CSF**. A) Schematic representation of fungal rRNA genes and the ITS1 sequence. Location of the primers employed for the PCR: primers 1 employed in the first PCR; primers 2A employed in the second PCR; primers 2B employed in the second PCR and previously described as panfungal primers. B) PCR was carried out as described from DNA samples obtained from CSF of ALS patients or controls. The primers employed were primers 1 for the first round PCR and primers 2A for the second round. After PCR, the samples were separated on agarose gels and stained with ethidium bromide. DNA size markers are shown on the left. Fungal species detected after sequencing each product is shown on the right. C) The samples obtained after the first PCR (primers 1) were amplified using primers 2B. PCR products were separated on agarose gels, extracted and sequenced. Fungal species detected are depicted on the right. Control PCR: PCR without DNA. CE: Control of DNA extraction without CFS DNA. 1: external primers. 2A: internal primers. 2B: panfungal primers.](ijbsv11p0546g002){#F2}

![**Immunohistochemistry analysis of brain sections from the frontal cortex of ALS patients.** Brain sections (frontal cortex) from ALS patients 9, 10 and 11 were observed with a confocal laser scanning microscope. Sections were obtained from fixed tissue and immunohistochemistry analyses were carried out. Sections were incubated with anti-*C. glabrata* antibodies (1:500 dilution), followed by incubation with secondary antibody donkey anti-rabbit IgG conjugated to Alexa 555 (1:500). Subsequently, sections were incubated with DAPI (1 μg/ml). The different panels in the figure are indicated. Scale bar: 10 μm.](ijbsv11p0546g003){#F3}

![**Immunohistochemistry analysis of brain sections from the frontal cortex of an ALS patient and a control.** Brain sections (frontal cortex) from ALS patient 11 and control 6 were observed with a confocal laser scanning microscope. Sections were obtained from fixed tissue and immunohistochemistry analyses were carried out. Double immunofluorescence assay using anti-tubulin and anti-*C. glabrata* antibodies was carried out as detailed in Materials and Methods. DAPI appears in blue and anti-*C. glabrata* is shown in green. Human tubulin appears in red. The different panels in the figure are indicated.](ijbsv11p0546g004){#F4}

![**PCR analysis of different brain regions from three ALS patients.** PCR was carried out as described. A) PCR analysis of different brain regions and controls using primers 1 and 2a. Table shows fungal species detected. B) PCR analysis of different brain regions and controls using primers 1 and 2b. Table shows fungal species detected. Control PCR: PCR without DNA. CE: Control of DNA extraction without CFS DNA. 1: external primers. 2A: internal primers. 2B: panfungal primers. FC: Frontal cortex. C: Cerebellum. O: Occipital cortex. WM: White matter. GM: Grey matter.](ijbsv11p0546g005){#F5}

![**Functional grouping of human proteins specifically present in the frontal cortex from ALS patients.**Human proteins which are common in the three ALS patients that are not present in control brain grouped by: a) cellular component; b) molecular function; c) protein class.](ijbsv11p0546g006){#F6}

###### 

Fungal antigens present in CSF from ALS patients immunoreacting with antibodies against different yeast species.

  Patients     *C.famata*   *C.albicans*   *C.glabrata*   *C.parapsilosis*   *Penicillium*   Enolase   β tubulin peptide
  ------------ ------------ -------------- -------------- ------------------ --------------- --------- -------------------
  Patient 1    88±2.7       164±6.6        118±4.7        42±2.9             56±3.9          183±5.5   280±8.4
  Patient 2    17±1.4       65±4.1         58±4.0         32±2.2             15±1.2          150±4.5   52±3.6
  Patient 3    2±0.2        180±7.2        14±1.1         5±0.4              129±5.2         130±3.9   144±5.8
  Patient 4    39±3.1       56±3.8         1±0.1          48±3.4             17±1.4          60±4.2    153±6.1
  Patient 5    58±4.1       191±7.6        7±0.6          13±1.0             20±1.6          78±3.6    55±3.8
  Mean value   40.8         131.2          39.6           28                 47.4            120.2     136.8
  Control 1    26±2.1       13±0.9         15±1.2         55±4.4             4±0.3           79±3.9    10±0.7
  Control 2    9±0.7        20±1.5         88±2.8         30±2.4             59±4.1          79±3.9    81±3.2
  Control 3    1±0.1        1±0.2          5±0.4          3±0.2              1±0.1           ND        1±0.2
  Mean value   12.0         11.3           33.3           29.3               21.3            79        30.6

The median of the densitometric values of three experiments and the standard deviation are indicated.

ND : not done

###### 

Proteomic analysis of fungal peptides present in brain samples from ALS patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patients        Total peptides fungi identified with PD 1.3   Peptides fungi not present in human database   Peptides fungi confirmed with peaks PTM and manual inspection   Certain fungal peptides
  --------------- --------------------------------------------- ---------------------------------------------- --------------------------------------------------------------- ------------------------------
  **Patient 6**                                                                                                                                                                

  Fraction A      159                                           27                                             0                                                               

  Fraction B      188                                           50                                             2                                                               AVLDLEPGTMDNVR β-tubulin\
                                                                                                                                                                               AVCMLSNTTAIAEAWSR. α-tubulin

  Fraction C      192                                           37                                             0                                                               

  Fraction D      103                                           15                                             0                                                               

  **Patient 7**                                                                                                                                                                

  Fraction A      212                                           48                                             0                                                               

  Fraction B      210                                           49                                             1                                                               AVCMLSNTTAIAEAWSR. α-tubulin

  Fraction C      213                                           33                                             0                                                               

  Fraction D      170                                           27                                             0                                                               

  **Patient 8**                                                                                                                                                                

  Fraction A      266                                           68                                             0                                                               

  Fraction B      207                                           48                                             1                                                               CVSMLSNTTAIAEAWSR. α-tubulin

  Fraction C      210                                           34                                             0                                                               

  Fraction D      187                                           31                                             0                                                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PD1.3: Proteome Discoverer 1.3 software
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